The role and influence of gut microbiota in pathogenesis and management of obesity and metabolic syndrome

Frontiers in Endocrinology

Volumn 5, Issue APR, 2014, Pages

  Parekh, Parth J ^a   Arusi, Eli ^a   Vinik, Aaron I ^a   Johnson, David A ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Insulin resistance; Metabolic syndrome; Microbiota; Obesity

Indexed keywords

FRUCTOSE OLIGOSACCHARIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIPOPROTEIN LIPASE; PREBIOTIC AGENT; PROBIOTIC AGENT; TOLL LIKE RECEPTOR 5;

BINDING AFFINITY; BODY WEIGHT; DIETARY INTAKE; HUMAN; INSULIN RESISTANCE; INTESTINE FLORA; LIPOGENESIS; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SATIETY;

EID: 84901032421     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00047     Document Type: Review

References (42)

1. Available from: http://www.cdc.gov/obesity/data/adult.html.
2. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest (2011) 121(6):2126-32. doi: 10.1172/JCI58109.
3. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science (2013) 341(6150):1241214. doi:10.1126/science.1241214.
4. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A (2004) 101(44):15718-23. doi:10.1073/pnas.0407076101.
5. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature (2006) 444(7122):1027-31. doi:10.1038/nature05414.
6. Jumpertz R, Le DS, Turnbaugh PJ, Trinidad C, Bogardus C, Gordon JI, et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr (2011) 94(1):58-65. doi:10.3945/ajcn.110.010132.
7. Lin HV, Frassetto A, Kowalik EJ Jr, Nawrocki AR, Lu MM, Kosinski JR, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One (2012) 7(4):e35240. doi:10.1371/journal.pone.0035240.
8. Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med (2013) 34(1):39-58. doi:10.1016/j.mam.2012.11.001.
9. Samuel BS, Gordon JI. A humanized gnotobiotic mouse model of host-archaeal-bacterial mutualism. Proc Natl Acad Sci U S A (2006) 103(26):10011-6. doi:10.1073/pnas.0602187103.
10. Conterno L, Fava F, Viola R, Tuohy KM. Obesity and the gut microbiota: does up-regulating colonic fermentation protect against obesity and metabolic disease? Genes Nutr (2011) 6(3):241-60. doi:10.1007/s12263-011-0230-1.
11. Schwiertz A, Taras D, Schäfer K, Beijer S, Bos NA, Donus C, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) (2010) 18(1):190-5. doi:10.1038/oby.2009.167.
12. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A (2007) 104(3):979-84. doi:10.1073/pnas.0605374104.
13. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol (1999) 277(1 Pt 1): E1-10.
14. Field BC, Wren AM, Peters V, Baynes KC, Martin NM, Patterson M, et al. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes (2010) 59(7):1635-9. doi:10.2337/db09-1859.
15. Page AJ, Symonds E, Peiris M, Blackshaw LA, Young RL. Peripheral neural targets in obesity. Br J Pharmacol (2012) 166(5):1537-58. doi:10.1111/j.1476-5381.2012.01951.x.
16. Karra E, Chandarana K, Batterham RL. The role of peptide YY in appetite regulation and obesity. J Physiol (2009) 587(Pt 1):19-25. doi:10.1113/jphysiol.2008.164269.
17. Darzi J, Frost GS, Robertson MD. Do SCFA have a role in appetite regulation? Proc Nutr Soc (2011) 70(1):119-28. doi:10.1017/S0029665110004039.
18. Cuche G, Cuber JC, Malbert CH. Ileal short-chain fatty acids inhibit gastric motility by a humoral pathway. Am J Physiol Gastrointest Liver Physiol (2000) 279(5):G925-30.
19. Bjursell M, Admyre T, Göransson M, Marley AE, Smith DM, Oscarsson J, et al. Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. Am J Physiol Endocrinol Metab (2011) 300(1):E211-20. doi:10.1152/ajpendo.00229.2010.
20. Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, Manchester JK, et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci U S A (2008) 105(43):16767-72. doi:10.1073/pnas.0808567105.
21. Go GW, Oh S, Park M, Gang G, McLean D, Yang HS, et al. t10,c12 Conjugated linoleic acid upregulates hepatic de novo lipogenesis and triglyceride synthesis via mTOR pathway activation. J Microbiol Biotechnol (2013) 23(11):1569-76. doi:10.4014/jmb.1308.08008.
22. Dasu MR, Ramirez S, IsseroffRR. Toll-like receptors and diabetes: a therapeutic perspective. Clin Sci (2012) 122(5):203-14. doi:10.1042/CS20110357.
23. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, et al. The innate immune response to bacterial flagellin is mediated by toll-like receptor 5. Nature (2001) 410(6832):1099-103. doi:10.1038/35074106.
24. Rhee SH. Basic and translational understandings of microbial recognition by toll-like receptors in the intestine. J Neurogastroenterol Motil (2011) 17(1):28-34. doi:10.5056/jnm.2011.17.1.28.
25. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, et al. Metabolic syndrome and altered gut microbiota in mice lacking toll-like receptor 5. Science (2010) 328(5975):228-31. doi:10.1126/science.1179721.
26. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A (2005) 102(31):11070-5. doi:10.1073/pnas.0504978102.
27. Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, Keilbaugh SA, Hamady M, Chen YY, et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology (2009) 137(5):e1-2. doi:10.1053/j.gastro.2009.08.042.
28. Fleissner CK, Huebel N, Abd El-Bary MM, Loh G, Klaus S, Blaut M. Absence of intestinal microbiota does not protect mice from diet-induced obesity. Br J Nutr (2010) 104(6):919-29. doi:10.1017/S0007114510001303.
29. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia (2007) 50(11):2374-83. doi:10.1007/s00125-007-0791-0.
30. Everard A, Lazarevic V, Derrien M, Girard M, Muccioli GG, Neyrinck AM, et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes (2011) 60(11):2775-86. doi:10.2337/db11-0227.
31. da Silva ST, Dos Santos CA, Bressan J. Intestinal microbiota; relevance to obesity and modulation by prebiotics and probiotics. Nutr Hosp (2013) 28(4):1039-48. doi:10.3305/nh.2013.28.4.6525.
32. Roberfroid MB. Functional foods: concepts and application to inulin and oligofructose. Br J Nutr (2002) 87(Suppl 2):S139-43. doi:10.1079/BJNBJN/2002529.
33. Parnell JA, Reimer RA. Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr (2009) 89(6):1751-9. doi:10.3945/ajcn.2009.27465.
34. Cassone M, Serra P, Mondello F, Girolamo A, Scafetti S, Pistella E, et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol (2003) 41(11):5340-3. doi:10.1128/JCM.41.11.5340-5343.2003.
35. Thygesen JB, Glerup H, Tarp B. Saccharomyces boulardii fungemia caused by treatment with a probioticum. BMJ Case Rep (2012) 2012. doi:10.1136/bcr.06.2011.4412.
36. Cohen L, Ranque S, Raoult D. Saccharomyces cerevisiae boulardii transient fungemia after intravenous self-inoculation. Med Mycol Case Rep (2013) 2:63-4. doi:10.1016/j.mmcr.2013.02.003.
37. Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol (2008) 49(5):821-30. doi:10.1016/j.jhep.2008.05.025.
38. Kadooka Y, Sato M, Imaizumi K, Ogawa A, Ikuyama K, Akai Y, et al. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr (2010) 64(6):636-43. doi:10.1038/ejcn.2010.19.
39. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol (2012) 9(2):88-96. doi:10.1038/nrgastro.2011.244.
40. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology (2012) 143(4):913. doi:10.1053/j.gastro.2012.06.031.
41. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes (2007) 56(7):1761-72. doi:10.2337/db06-1491.
42. Van Greevenbroek MM, Schalkwijk CG, Stehouwer CD. Obesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences. Neth J Med (2013) 71(4):174-87.